{"id":"rifampicin-rif","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"common","effect":"Orange/red discoloration of body fluids"},{"rate":"1-5","effect":"Rash"},{"rate":"1-3","effect":"Gastrointestinal disturbance"},{"rate":"<1","effect":"Thrombocytopenia"},{"rate":"common","effect":"Drug-drug interactions (enzyme induction)"}]},"_chembl":null,"_dailymed":{"setId":"6dd0e7ca-f136-4d68-9c44-5a729eda0cec","title":"RIFAMPIN (RIFAMPICIN) POWDER [EVEREEN SHANGHAI BIOTECHNOLOGY LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin binds to the bacterial RNA polymerase enzyme and blocks the path of elongating RNA transcripts, effectively halting bacterial gene expression. This mechanism is highly selective for prokaryotic RNA polymerase and has minimal effect on eukaryotic enzymes. The drug is bactericidal and is particularly effective against Mycobacterium tuberculosis and other mycobacterial species.","oneSentence":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:17.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB"},{"name":"Leprosy (Hansen's disease)"},{"name":"Atypical mycobacterial infections (MAC, M. marinum)"},{"name":"Brucellosis"},{"name":"Legionellosis"}]},"trialDetails":[{"nctId":"NCT04930744","phase":"PHASE2","title":"Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-08-26","conditions":"Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection","enrollment":112},{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT07374224","phase":"PHASE1","title":"A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2026-03-05","conditions":"Clinical Pharmacology","enrollment":28},{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT07350174","phase":"PHASE2","title":"Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-03-30","conditions":"Tuberculosis Meningitis","enrollment":64},{"nctId":"NCT07440160","phase":"NA","title":"Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arba Minch University","startDate":"2025-07-01","conditions":"Tuberculosis","enrollment":278},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT07429331","phase":"PHASE1","title":"Drug Interaction and Food Effect Study of CS0159","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-03","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT00750841","phase":"PHASE1","title":"Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2008-09-09","conditions":"Solid Tumors","enrollment":64},{"nctId":"NCT05556746","phase":"PHASE2","title":"Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-24","conditions":"Tuberculosis, Pulmonary, HIV","enrollment":94},{"nctId":"NCT07420881","phase":"NA","title":"Start4All - Start Taking Action for TB Diagnosis (DARE-TB)","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2026-03-01","conditions":"TB - Tuberculosis","enrollment":60000},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT02701608","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":"Infective Endocarditis","enrollment":162},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT06498414","phase":"PHASE2, PHASE3","title":"Shorter and Safer Treatment Regimens for Latent TB","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-06-10","conditions":"Tuberculosis Infection, Latent","enrollment":1800},{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT07069582","phase":"PHASE1","title":"Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-04-01","conditions":"Tuberculosis Infection, Healthy Volunteer, Breastfeeding","enrollment":60},{"nctId":"NCT05117788","phase":"","title":"Bioneer Q-RFIA Clinical Evaluation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Innovative New Diagnostics, Switzerland","startDate":"2022-02-23","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":2350},{"nctId":"NCT05372367","phase":"PHASE1","title":"A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-08-11","conditions":"Solid Tumors","enrollment":33},{"nctId":"NCT03672630","phase":"PHASE2, PHASE3","title":"Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease","status":"COMPLETED","sponsor":"Kevin Winthrop","startDate":"2019-02-22","conditions":"Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection","enrollment":474},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT06318416","phase":"PHASE1","title":"Precision Rifampin Trial for Personalized Dosing","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-10-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":"Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis","enrollment":280},{"nctId":"NCT07357610","phase":"PHASE1","title":"An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":"Healthy Adult Participants","enrollment":60},{"nctId":"NCT06057519","phase":"PHASE3","title":"Pragmatic Optimized Rifampicin Trial","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-01-16","conditions":"Tuberculosis, Pulmonary","enrollment":164},{"nctId":"NCT06441006","phase":"PHASE2, PHASE3","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-10-03","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":400},{"nctId":"NCT07345325","phase":"PHASE3","title":"Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-01","conditions":"Infective Endocarditis","enrollment":422},{"nctId":"NCT03012529","phase":"PHASE4","title":"Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-01-22","conditions":"Osteomyelitis, Diabetes, Amputation","enrollment":843},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":"Osteomyelitis - Foot","enrollment":""},{"nctId":"NCT07073638","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis","status":"RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2025-10-13","conditions":"Pulmonary Tuberculoses","enrollment":24},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Sepsis, Tuberculosis","enrollment":344},{"nctId":"NCT07330531","phase":"PHASE4","title":"Drug-drug Interaction Study of Rifampin and Anaprazole Sodium","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2026-01-04","conditions":"Drug-drug Interaction Study","enrollment":24},{"nctId":"NCT04951986","phase":"PHASE3","title":"Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cape Town","startDate":"2021-08-11","conditions":"Disseminated Tuberculosis, HIV","enrollment":732},{"nctId":"NCT06489431","phase":"PHASE3","title":"Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2023-12-04","conditions":"Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation","enrollment":200},{"nctId":"NCT07134478","phase":"PHASE1","title":"Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-10-28","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT07313215","phase":"NA","title":"Rifampin-combined Antibiotic Therapy for Staphylococcal PJI","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-11-13","conditions":"Periprosthetic Joint Infection","enrollment":428},{"nctId":"NCT07242781","phase":"PHASE1","title":"A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-12-15","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT06022146","phase":"PHASE3","title":"TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-09-01","conditions":"Tuberculosis, Latent Tuberculosis","enrollment":3520},{"nctId":"NCT05822544","phase":"PHASE1","title":"Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes","status":"RECRUITING","sponsor":"OrsoBio, Inc","startDate":"2023-04-22","conditions":"Healthy Subjects, Obesity, Type 2 Diabetes","enrollment":564},{"nctId":"NCT05592223","phase":"PHASE1","title":"Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-06","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT04606537","phase":"PHASE1","title":"Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects","status":"COMPLETED","sponsor":"KBP Biosciences","startDate":"2020-10-24","conditions":"Healthy, Drug Drug Interaction","enrollment":24},{"nctId":"NCT05118490","phase":"PHASE4","title":"Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-07-19","conditions":"HIV Seropositivity, Tuberculosis, Household Contact","enrollment":1000},{"nctId":"NCT06024915","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-09-21","conditions":"Myelofibrosis","enrollment":40},{"nctId":"NCT07253688","phase":"PHASE3","title":"Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2025-11-10","conditions":"Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis","enrollment":330},{"nctId":"NCT07268664","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-12-01","conditions":"Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":120},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05069688","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-07","conditions":"Pediatric HIV Infection, Tuberculosis Infection","enrollment":20},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT07018635","phase":"PHASE1","title":"A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2025-07-16","conditions":"Healthy Participants","enrollment":63},{"nctId":"NCT02539407","phase":"","title":"Population Pharmacokinetics of Anti-infectives in Critically Ill Children","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-11","conditions":"Pediatric Intensive Care Unit, Pediatric Immuno-hematology Department","enrollment":3000},{"nctId":"NCT06585020","phase":"PHASE2","title":"Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2024-10-20","conditions":"Mycobacterium; Xenopi, Lung Diseases","enrollment":190},{"nctId":"NCT03236987","phase":"PHASE3","title":"CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2018-02-05","conditions":"Lung Infection, MAC Lung Disease","enrollment":424},{"nctId":"NCT04923958","phase":"NA","title":"Rapid Research in Diagnostics Development for TB Network","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-04-14","conditions":"Tuberculosis","enrollment":26436},{"nctId":"NCT07227779","phase":"PHASE2","title":"B-PaLMZ for TB Meningitis","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-15","conditions":"Tuberculous Meningitis","enrollment":240},{"nctId":"NCT06205589","phase":"PHASE2","title":"Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB","status":"NOT_YET_RECRUITING","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2026-02-15","conditions":"Tuberculosis, Pulmonary","enrollment":1500},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05671718","phase":"NA","title":"Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-09-04","conditions":"Drug Resistant Tuberculosis","enrollment":2944},{"nctId":"NCT07213765","phase":"PHASE4","title":"Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease","status":"RECRUITING","sponsor":"Bin Cao","startDate":"2025-07-24","conditions":"Mycobacterium Avium Complex Pulmonary Disease","enrollment":188},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT05382312","phase":"PHASE2","title":"Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-07-26","conditions":"Tuberculosis","enrollment":127},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT07196449","phase":"PHASE1","title":"Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2025-05-14","conditions":"Drug Drug Interaction (DDI)","enrollment":12},{"nctId":"NCT07191834","phase":"","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid","enrollment":60},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT06497465","phase":"PHASE3","title":"Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-18","conditions":"Tuberculosis, HIV","enrollment":150},{"nctId":"NCT05526885","phase":"NA","title":"Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa","status":"COMPLETED","sponsor":"Klaus Reither","startDate":"2022-09-07","conditions":"Tuberculosis","enrollment":20000},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT05338489","phase":"PHASE1","title":"A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-05-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT07084402","phase":"PHASE4","title":"Short-term Bactericidal Effect of Contezolid in MAC-PD","status":"RECRUITING","sponsor":"Bin Cao","startDate":"2025-07-24","conditions":"Mycobacterium Avium Complex Pulmonary Disease","enrollment":188},{"nctId":"NCT06064539","phase":"PHASE1","title":"Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-18","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT06222372","phase":"NA","title":"Novel Interventions and Diagnostic Tests for Leprosy","status":"RECRUITING","sponsor":"Annemieke Geluk","startDate":"2020-03-04","conditions":"Leprosy","enrollment":1100},{"nctId":"NCT07014488","phase":"PHASE1","title":"A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-06-20","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT05473520","phase":"PHASE3","title":"Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-05-24","conditions":"Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)","enrollment":150},{"nctId":"NCT07163143","phase":"PHASE3","title":"Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2025-11","conditions":"Tuberculosis (TB)","enrollment":784},{"nctId":"NCT02906007","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-09-21","conditions":"Tuberculosis, HIV","enrollment":54},{"nctId":"NCT07155408","phase":"NA","title":"Combined Use of Povidone-Iodine and Rifampicin in Hair Transplantation","status":"COMPLETED","sponsor":"Elif Asena KANTARCI","startDate":"2021-12-02","conditions":"Androgenetic Alopecia, Wound Healing","enrollment":65},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT06446245","phase":"PHASE2","title":"Adjunctive Doxycycline for Central Nervous System Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-08-21","conditions":"Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System","enrollment":200},{"nctId":"NCT04311502","phase":"PHASE2","title":"Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-05","conditions":"HIV, Tuberculosis","enrollment":104},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05473195","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2022-12-06","conditions":"Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)","enrollment":105},{"nctId":"NCT04521803","phase":"PHASE2","title":"High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis","status":"RECRUITING","sponsor":"University of Cape Town","startDate":"2022-01-10","conditions":"Tuberculous Pericarditis, HIV Status","enrollment":60},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT04921943","phase":"PHASE4","title":"Hypertonic Saline for MAC","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2021-05-18","conditions":"Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection","enrollment":50},{"nctId":"NCT07056842","phase":"PHASE1","title":"This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2025-07-20","conditions":"Obesity &Amp; Overweight","enrollment":32},{"nctId":"NCT07118696","phase":"PHASE3","title":"Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2026-02-01","conditions":"Pulmonary TB","enrollment":1000},{"nctId":"NCT03301038","phase":"PHASE2","title":"Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2018-07-25","conditions":"Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1320,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rifampicin (RIF)","genericName":"Rifampicin (RIF)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB, Leprosy (Hansen's disease), Atypical mycobacterial infections (MAC, M. marinum).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}